Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma-Reference-Cited by-同舟云学术

Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma

Published:2020-05 Issue:5 Volume:140 Page:1045-1053.e6
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Bresin Antonella^ORCID,Cristofoletti Cristina^ORCID,Caprini Elisabetta^ORCID,Cantonetti Maria^ORCID,Monopoli Alessandro^ORCID,Russo Giandomenico^ORCID,Narducci Maria Grazia^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute - Ricerca Corrente, Italy

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference59 articles.

1. First-in-human pharmacokinetic and Pharmacodynamic Study of the dual m-TORC 1/2 Inhibitor AZD2014;Basu;Clin Cancer Res,2015

2. Introduction to digital PCR;Bizouarn;Methods Mol Biol,2014

3. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eμ-TCL1 mouse model;Blunt;Blood,2015

4. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts;Brana;Oncotarget,2017

5. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays;Caprini;Cancer Res,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEPTOR levels in patients with mycosis fungoides;Dermatologica Sinica;2024-09-12

2. “Next top” mouse models advancing CTCL research;Frontiers in Cell and Developmental Biology;2024-04-10

3. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides;Scientific Reports;2024-01-23

4. Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment;Frontiers in Immunology;2024-01-11

5. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma;Frontiers in Immunology;2023-12-22